UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 183

Sortiert nach

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

Molecular cell, 2018-08, Vol.71 (4), p.606-620.e7

2018

Volltextzugriff (PDF)

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state

Science translational medicine, 2019-04, Vol.11 (488)

2019

Volltextzugriff (PDF)

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

Journal of clinical oncology, 2012-03, Vol.30 (8), p.777-782

2012

Volltextzugriff (PDF)

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

Cell reports (Cambridge), 2014-01, Vol.6 (2), p.377-387

2014

Volltextzugriff (PDF)

High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer

Nature communications, 2018-11, Vol.9 (1), p.5079-17, Article 5079

2018

Volltextzugriff (PDF)

Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

Breast cancer research : BCR, 2020-06, Vol.22 (1), p.69-69, Article 69

2020

Volltextzugriff (PDF)

Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma

Human pathology, 2021-02, Vol.108, p.42-50

2021

Volltextzugriff (PDF)

Comparative Effectiveness of an mTOR‐Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple‐Negative Breast Cancer

The oncologist (Dayton, Ohio), 2018-11, Vol.23 (11), p.1300-1309

2018

Volltextzugriff (PDF)

Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer

Clinical cancer research, 2016-01, Vol.22 (1), p.26-33

2016

Volltextzugriff (PDF)

Impact of TP53 mutations in Triple Negative Breast Cancer

NPJ precision oncology, 2022-09, Vol.6 (1), p.64-64, Article 64

2022

Volltextzugriff (PDF)

Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field

The oncologist (Dayton, Ohio), 2017-09, Vol.22 (9), p.1086-1093

2017

Volltextzugriff (PDF)

A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer

Clinical cancer research, 2008-10, Vol.14 (19), p.6277-6283

2008

Volltextzugriff (PDF)

Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

The New England journal of medicine, 2016-07, Vol.375 (1), p.23-34

2016

Volltextzugriff (PDF)

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant

Journal of clinical oncology, 2020-02, Vol.38 (5), p.388-394

2020

Volltextzugriff (PDF)

Adaptive Randomization of Neratinib in Early Breast Cancer

The New England journal of medicine, 2016-07, Vol.375 (1), p.11-22

2016

Volltextzugriff (PDF)

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

NPJ breast cancer, 2022-05, Vol.8 (1), p.64-64, Article 64

2022

Volltextzugriff (PDF)

Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer

NPJ breast cancer, 2023-01, Vol.9 (1), p.2-2, Article 2

2023

Volltextzugriff (PDF)

Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2 + -Advanced Solid Tumors, with an Expansion Cohort in HER2 + Metastatic Breast Cancer (MBC)

Clinical cancer research, 2017-07, Vol.23 (14), p.3529-3536

2017

Volltextzugriff (PDF)

Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer

Clinical cancer research, 2008-12, Vol.14 (23), p.7909-7916

2008

Volltextzugriff (PDF)

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

Molecular cancer therapeutics, 2011-03, Vol.10 (3), p.558-565

2011

Volltextzugriff (PDF)

Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy

Clinical cancer research, 2024-06, Vol.30 (11), p.2424

2024

Volltextzugriff (PDF)

Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity

Molecular cancer therapeutics, 2011-07, Vol.10 (7), p.1300-1307

2011

Volltextzugriff (PDF)

Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer

Clinical cancer research, 2021-10, Vol.27 (19), p.5365-5375

2021

Volltextzugriff (PDF)

Leptomeningeal disease and breast cancer: the importance of tumor subtype

Breast cancer research and treatment, 2014-08, Vol.146 (3), p.477-486

2014

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(175)

Publikationsform

Artikel
(183)

Sprache

Englisch
(183)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Science & Technology
(83)
Life Sciences & Biomedicine
(80)
Humans
(73)
Female
(70)
Oncology
(67)
Breast Cancer
(50)
Middle Aged
(48)
Adult
(46)
Aged
(43)
Breast Neoplasms - Drug Therapy
(37)
Tumors
(36)
Breast Neoplasms - Pathology
(28)
Patients
(24)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(23)
Chemotherapy
(21)
Treatment Outcome
(21)
Metastasis
(20)
Biological And Medical Sciences
(19)
Medical Sciences
(19)
Medicine
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer

Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma

Comparative Effectiveness of an mTOR‐Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple‐Negative Breast Cancer

Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer

Impact of TP53 mutations in Triple Negative Breast Cancer

Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field

A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer

Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant

Adaptive Randomization of Neratinib in Early Breast Cancer

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer

Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2 + -Advanced Solid Tumors, with an Expansion Cohort in HER2 + Metastatic Breast Cancer (MBC)

Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy

Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity

Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab

Leptomeningeal disease and breast cancer: the importance of tumor subtype

Aktive Filter

Suchergebnisse filtern